Amgen Reports Results of Blincyto (blinatumomab) in Two P-III Studies for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

 Amgen Reports Results of Blincyto (blinatumomab) in Two P-III Studies for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

Amgen Reports Results of Blincyto (blinatumomab) in Two P-III Studies for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

Shots:

  • The P-III 20120215 study involves assessing of Blincyto vs SoC consolidation CT in pediatric patients with high-risk first relapsed B-cell ALL, being conducted as part of the PIP agreed b/w Amgen & the EMA, resulted in meeting its 1EPs of event-free survival
  • The P-III COG AALL1331 study involves assessing of Blincyto +CT vs CT as monothx. to evaluate DFS of HR/IR relapsed B-ALL patients who are randomized following induction block 1 CT to receive either two intensive CT blocks or two 5-wks. blocks of blinatumomab
  • Blincyto is a bispecific CD19-directed CD3 T cell engager (BiTE) Ab designed to bind CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. The two P-III studies were stopped early due to treatment benefits of Blincyto over CT

Click here to­ read full press release/ article | Ref: Amgen | Image: The Wall Street Journal

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post